Mr. Michel Baijot adds ASIT Biotech is an innovative company in the field of allergy immunotherapy. ASIT Biotech’s teams have accomplished exceptional work that has led to a Phase III study whose success is the pivotal factor for the Company’s future. I am very enthusiastic about the prospects that this Phase III study gives a glimpse of. As Managing Director, my first task consists in defining the Company’s priorities and aligning the necessary resources. I will then provide the Board with my proposals in terms of our organization and the means we need to mobilize to reach these objectives. I firmly believe that the combined knowledge and expertise of the members of this new Board of Directors will enable us, with ASIT Biotech’s teams, to develop the technological platform that satisfies patients who are awaiting new treatments for allergies.